Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group, „The Lancet”, 352 (9131), 1998, s. 854–865, DOI: 10.1016/S0140-6736(98)07037-8, PMID: 9742977(ang.).
MarzenaM.GrzybowskaMarzenaM., JoannaJ.BoberJoannaJ., MariaM.OlszewskaMariaM., Metformina – mechanizmy działania i zastosowanie w terapii cukrzycy typu 2, „Postępy Higieny i Medycyny Doświadczalnej”, 65, 2011, s. 277–285, DOI: 10.5604/17322693.941655.
AlejandroA.Martin-MontalvoAlejandroA. i inni, Metformin improves healthspan and lifespan in mice, „Nature Communications”, 4, 2013, DOI: 10.1038/ncomms3192, PMID: 23900241, PMCID: PMC3736576(ang.).
LucydalilaL.CedilloLucydalilaL. i inni, Ether lipid biosynthesis promotes lifespan extension and enables diverse pro-longevity paradigms in Caenorhabditis elegans, „eLife”, 12, 2023, DOI: 10.7554/eLife.82210, PMID: 37606250, PMCID: PMC10444025 [dostęp 2024-01-24](ang.).
AnnaA.MarkowskaAnnaA., StefanS.SajdakStefanS., JaninaJ.MarkowskaJaninaJ., AdamA.HuczyńskiAdamA., Could there be a role for the antidiabetic drug metformin in oncological treatment?, „European Journal of Gynecological Oncology”, 39 (6), 2018, s. 867–870, DOI: 10.12892/ejgo4677.2018(ang.).
Josie M.M.J.M.M.EvansJosie M.M.J.M.M., Louise A.L.A.DonnellyLouise A.L.A., Alistair M.A.M.Emslie-SmithAlistair M.A.M., Dario R.D.R.AlessiDario R.D.R., Andrew D.A.D.MorrisAndrew D.A.D., Metformin and reduced risk of cancer in diabetic patients, „British Medical Journal”, 330 (7503), 2005, s. 1304–1305, DOI: 10.1136/bmj.38415.708634.F7(ang.).
Heather A.H.A.HirschHeather A.H.A., DimitriosD.IliopoulosDimitriosD., Philip N.P.N.TsichlisPhilip N.P.N., KevinK.StruhlKevinK., Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission, „Cancer Research”, 69 (19), 2009, s. 7507–7511, DOI: 10.1158/0008-5472.CAN-09-2994, PMID: 19752085, PMCID: PMC2756324(ang.).
Gijs W.D.G.W.D.LandmanGijs W.D.G.W.D. i inni, Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16, „Diabetes Care”, 33 (2), 2010, s. 322–326, DOI: 10.2337/dc09-1380, PMID: 19918015, PMCID: PMC2809274(ang.).
Jared M.J.M.CampbellJared M.J.M., Susan M.S.M.BellmanSusan M.S.M., Matthew D.M.D.StephensonMatthew D.M.D., KarolinaK.LisyKarolinaK., Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis, „Ageing Research Reviews”, 40, 2017, s. 31–44, DOI: 10.1016/j.arr.2017.08.003(ang.).
JamesJ.McCormackJamesJ., KevinK.JohnsKevinK., HughH.TildesleyHughH., Metformin’s contraindications should be contraindicated, „Canadian Medical Association Journal”, 173 (5), 2005, s. 502–504, DOI: 10.1503/cmaj.045292, PMID: 16129871, PMCID: PMC1188187(ang.).
A.A.HolsteinA.A., M.M.StumvollM.M., Contraindications can damage your health-is metformin a case in point?, „Diabetologia”, 48 (12), 2005, s. 2454–5459, DOI: 10.1007/s00125-005-0026-1, PMID: 16283245(ang.).
Jolien deJ.JagerJolien deJ. i inni, Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial, „British Medical Journal”, 340, 2010, c2181, DOI: 10.1136/bmj.c2181, PMID: 20488910, PMCID: PMC2874129(ang.).
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group, „The Lancet”, 352 (9131), 1998, s. 854–865, DOI: 10.1016/S0140-6736(98)07037-8, PMID: 9742977(ang.).
AlejandroA.Martin-MontalvoAlejandroA. i inni, Metformin improves healthspan and lifespan in mice, „Nature Communications”, 4, 2013, DOI: 10.1038/ncomms3192, PMID: 23900241, PMCID: PMC3736576(ang.).
LucydalilaL.CedilloLucydalilaL. i inni, Ether lipid biosynthesis promotes lifespan extension and enables diverse pro-longevity paradigms in Caenorhabditis elegans, „eLife”, 12, 2023, DOI: 10.7554/eLife.82210, PMID: 37606250, PMCID: PMC10444025 [dostęp 2024-01-24](ang.).
Heather A.H.A.HirschHeather A.H.A., DimitriosD.IliopoulosDimitriosD., Philip N.P.N.TsichlisPhilip N.P.N., KevinK.StruhlKevinK., Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission, „Cancer Research”, 69 (19), 2009, s. 7507–7511, DOI: 10.1158/0008-5472.CAN-09-2994, PMID: 19752085, PMCID: PMC2756324(ang.).
Gijs W.D.G.W.D.LandmanGijs W.D.G.W.D. i inni, Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16, „Diabetes Care”, 33 (2), 2010, s. 322–326, DOI: 10.2337/dc09-1380, PMID: 19918015, PMCID: PMC2809274(ang.).
JamesJ.McCormackJamesJ., KevinK.JohnsKevinK., HughH.TildesleyHughH., Metformin’s contraindications should be contraindicated, „Canadian Medical Association Journal”, 173 (5), 2005, s. 502–504, DOI: 10.1503/cmaj.045292, PMID: 16129871, PMCID: PMC1188187(ang.).
A.A.HolsteinA.A., M.M.StumvollM.M., Contraindications can damage your health-is metformin a case in point?, „Diabetologia”, 48 (12), 2005, s. 2454–5459, DOI: 10.1007/s00125-005-0026-1, PMID: 16283245(ang.).
Jolien deJ.JagerJolien deJ. i inni, Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial, „British Medical Journal”, 340, 2010, c2181, DOI: 10.1136/bmj.c2181, PMID: 20488910, PMCID: PMC2874129(ang.).